<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889055</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.111</org_study_id>
    <nct_id>NCT02889055</nct_id>
  </id_info>
  <brief_title>Evaluation of Mirus™ for Sedation in Resuscitation</brief_title>
  <acronym>MIRUS</acronym>
  <official_title>Evaluation of Mirus™ for Sedation in Resuscitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current recommendations for the conduct of sédationanalgésie ICU encourage the use of the
      lightest possible sedation strategies, avoiding the administration of benzodiazepines source
      of longer durations of ventilation and ICU stay of syndrome cessation, mental confusion.
      Among the proposed alternatives, administration of halogenated volatile agents (sevoflurane)
      in resuscitation is interesting because their favorable pharmacokinetic even after prolonged
      administration: no tachyphylaxis, rapid clearance, no withdrawal syndrome.

      There are two suitable delivery devices sevoflurane in intensive care, both with CE marking.
      The device Mirus ™ (Pall Medical, Fribourg, Switzerland) is the newest and it is easy to use
      and reliable. The objective of this study was to evaluate the use of Mirus ™ device in trauma
      resuscitation and cardiovascular resuscitation.

      Specifically, it will use this modality in case of failure with conventional sedation
      products (propofol, midazolam): maximum permissible doses, sedation weaning failure due to
      severe agitation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ead-time (in minutes) of sevoflurane sedation for obtaining a target RASS score between 1 (anxious) and 2 (mild sedation).</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Patient Requiring Mechanical Ventilation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>patient requiring the MIRUS (mechanical ventilation)</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient requiring mechanical ventilation for more than 48 hours
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18 years

          -  In mechanical ventilation for more than 48 hours

          -  No intracranial hypertension

          -  In severe state of agitation measured by a sedation scale score greater than 2 RASS

          -  Agitation observed in two circumstances: receiving maximal doses of propofol (≥ 5 mg /
             kg / h) and / or midazolam (≥ 0.2 mg / kg / h), or weaning failure to stop the
             sedation agitation.

        Exclusion Criteria:

          -  Presence of a severe head injury (Glasgow initial score between 3 and 8) requiring
             monitoring intracranial pressure and / or treatment of intracranial hypertension

          -  Sedation with dexmedetomidine

          -  Personal or family antecedent of anesthetic malignant hyperthermia

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François PAYEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François PAYEN, MD</last_name>
    <phone>04 76 76 92 88</phone>
    <email>JFPayen@cju-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphane COMBAZ</last_name>
    <email>SCombaz@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François PAYEN, MD</last_name>
      <email>JFPayen@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013 Jan;41(1):263-306. doi: 10.1097/CCM.0b013e3182783b72. Review.</citation>
    <PMID>23269131</PMID>
  </reference>
  <reference>
    <citation>Kong KL, Willatts SM, Prys-Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unit. BMJ. 1989 May 13;298(6683):1277-80.</citation>
    <PMID>2500195</PMID>
  </reference>
  <reference>
    <citation>Sackey PV, Martling CR, Carlswärd C, Sundin O, Radell PJ. Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study. Crit Care Med. 2008 Mar;36(3):801-6. doi: 10.1097/CCM.0B013E3181652FEE.</citation>
    <PMID>18431266</PMID>
  </reference>
  <reference>
    <citation>Sackey PV, Martling CR, Granath F, Radell PJ. Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med. 2004 Nov;32(11):2241-6.</citation>
    <PMID>15640636</PMID>
  </reference>
  <reference>
    <citation>Mesnil M, Capdevila X, Bringuier S, Trine PO, Falquet Y, Charbit J, Roustan JP, Chanques G, Jaber S. Long-term sedation in intensive care unit: a randomized comparison between inhaled sevoflurane and intravenous propofol or midazolam. Intensive Care Med. 2011 Jun;37(6):933-41. doi: 10.1007/s00134-011-2187-3. Epub 2011 Mar 29.</citation>
    <PMID>21445642</PMID>
  </reference>
  <reference>
    <citation>Röhm KD, Wolf MW, Schöllhorn T, Schellhaass A, Boldt J, Piper SN. Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery. Intensive Care Med. 2008 Sep;34(9):1683-9. doi: 10.1007/s00134-008-1157-x. Epub 2008 May 24.</citation>
    <PMID>18500419</PMID>
  </reference>
  <reference>
    <citation>Hellström J, Öwall A, Bergström J, Sackey PV. Cardiac outcome after sevoflurane versus propofol sedation following coronary bypass surgery: a pilot study. Acta Anaesthesiol Scand. 2011 Apr;55(4):460-7. doi: 10.1111/j.1399-6576.2011.02405.x. Epub 2011 Feb 22.</citation>
    <PMID>21342154</PMID>
  </reference>
  <reference>
    <citation>Soukup J, Schärff K, Kubosch K, Pohl C, Bomplitz M, Kompardt J. State of the art: sedation concepts with volatile anesthetics in critically Ill patients. J Crit Care. 2009 Dec;24(4):535-44. doi: 10.1016/j.jcrc.2009.01.003. Epub 2009 Mar 27. Review.</citation>
    <PMID>19327951</PMID>
  </reference>
  <reference>
    <citation>Perbet S, Bourdeaux D, Sautou V, Pereira B, Chabanne R, Constantin JM, Chopineau J, Bazin JE. A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa®) in ICU patients. Minerva Anestesiol. 2014 Jun;80(6):655-65. Epub 2013 Nov 13.</citation>
    <PMID>24226486</PMID>
  </reference>
  <reference>
    <citation>Chabanne R, Perbet S, Futier E, Ben Said NA, Jaber S, Bazin JE, Pereira B, Constantin JM. Impact of the anesthetic conserving device on respiratory parameters and work of breathing in critically ill patients under light sedation with sevoflurane. Anesthesiology. 2014 Oct;121(4):808-16. doi: 10.1097/ALN.0000000000000394.</citation>
    <PMID>25111218</PMID>
  </reference>
  <reference>
    <citation>Sackey PV, Martling CR, Nise G, Radell PJ. Ambient isoflurane pollution and isoflurane consumption during intensive care unit sedation with the Anesthetic Conserving Device. Crit Care Med. 2005 Mar;33(3):585-90.</citation>
    <PMID>15753751</PMID>
  </reference>
  <reference>
    <citation>Berton J, Sargentini C, Nguyen JL, Belii A, Beydon L. AnaConDa reflection filter: bench and patient evaluation of safety and volatile anesthetic conservation. Anesth Analg. 2007 Jan;104(1):130-4.</citation>
    <PMID>17179257</PMID>
  </reference>
  <reference>
    <citation>Bomberg H, Glas M, Groesdonk VH, Bellgardt M, Schwarz J, Volk T, Meiser A. A novel device for target controlled administration and reflection of desflurane--the Mirus™. Anaesthesia. 2014 Nov;69(11):1241-50. doi: 10.1111/anae.12798. Epub 2014 Jul 9.</citation>
    <PMID>25040673</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

